Université de Rouen, Mont-Saint-Aignan, France.
Paris Nanterre University, France.
J Atten Disord. 2021 Aug;25(10):1347-1350. doi: 10.1177/1087054720905664. Epub 2020 Feb 17.
Prevalence estimates for ADHD have been debated for decades. In France, the only available study states the prevalence rate in France ranges from 3.5% to 5.6% of children aged 6 to 12. It also evaluates that 3.48% of children aged 6 to 12 are treated with psychostimulants. The article uses a different method to determine whether these estimates hold true. Estimating ADHD diagnosis and methylphenidate prescription rates can be done by analyzing national health care insurance system's data. We used data from the French Healthcare Insurance as reported by the National Agency for Medicines and Health Products Safety. We claim that an adequate estimate of the ADHD prevalence rate in France fluctuates around 0.3% of children aged 6 to 11. Methodological biases in ADHD prevalence studies and factors contributing to the low level of prescription in France need to be assessed. We call for supplementary investigations in health care insurance databases to conduct contradictory studies.
注意缺陷多动障碍(ADHD)的流行率估计值已经争论了几十年。在法国,唯一可用的研究表明,6 至 12 岁儿童的 ADHD 流行率范围为 3.5%至 5.6%。该研究还评估了 6 至 12 岁儿童中有 3.48%接受了精神兴奋剂治疗。本文使用了一种不同的方法来确定这些估计值是否正确。通过分析国家健康保险系统的数据,可以确定 ADHD 的诊断和哌醋甲酯处方率。我们使用了法国国家药品和保健品安全局报告的法国医疗保险数据。我们声称,法国 6 至 11 岁儿童的 ADHD 流行率估计值在 0.3%左右波动。需要评估 ADHD 流行率研究中的方法学偏差以及导致法国处方率低的因素。我们呼吁在医疗保险数据库中进行补充调查,以开展对比研究。